Journal profile · Medicine-Pharmacology (medical)
Journal of Experimental Pharmacology
ISSN 1179-1454 · Dove Medical Press · United Kingdom
Journal of Experimental Pharmacology: fully open access; APC about USD 3,940; median 104 days to acceptance (75 articles, last 24 months); acceptance rate 19% (journal website); 51 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Journal of Experimental Pharmacology is published by Dove Medical Press. By OpenAlex counts of its recent articles, its largest topics are Medicinal Plant Research, Phytochemistry Medicinal Plant Applications and Natural Antidiabetic Agents Studies, together about 44.8% of its articles. Its main subfields are Plant Science. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Abdelwahab Omri The Journal of Experimental Pharmacology (JEP) is an esteemed international, peer-reviewed, open-access online journal covering various aspects of laboratory and experimental pharmacology. JEP serves as a platform for disseminating cutting-edge discoveries in the field, facilitating advancements and discussions in experimental pharmacology and related disciplines. The journal aims to be a leading platform for researchers and scholars to share innovative discoveries and contribute to the development of new therapeutic strategies. Authors are encouraged to submit manuscripts that align with the journal's focus on original experimental research. The Journal of Experimental Pharmacology does not consider meta-analyses for publication. The journal’s audience includes pharmaceutical chemist, Clinicians, Principal investigators with academic and industry profiles interested in submissions with areas of focus across a broad spectrum of topics within experimental pharmacology and related areas, including but not limited to:
· Experimental Pharmacology and Physiology
· Cardiovascular Disease
· Drug Discovery/Translational and Development
· Mechanisms of Drug Action
· Experimental Models in Pharmacology
· Molecular Pharmacology
· Cellular Pharmacology
· Neuropharmacology
· Immunopharmacology
· Toxicology and Safety Pharmacology
· Pharmacogenomics and Precision Medicine
· Biochemical Pharmacology
· Pharmacological Interventions
· Novel Drug Targets and Techniques
· Drug Metabolism & Disposition
· Vaccine Development
· Tissue Replacement
· Immunotherapies
· Pharmacogenomics
· Pharmacoepidemiology
· Experimental Therapeutic Strategies
· Endocrine Pharmacology
· Gastrointestinal Pharmacology
· Musculoskeletal Pharmacology
· Skin Pharmacology
· Hepatic Pharmacology
· Pulmonary Pharmacology
· Pharmacology of Allergic Diseases
· Pharmacology of Autoimmune Diseases
· Renal/Urinary Pharmacology
· Reproductive Pharmacology
· Anti-Infective Drugs
· Chemotherapy The journal welcomes for consideration the following article types: original research article, reviews, reports, commentaries. All submissions undergo rigorous single-anonymous peer review by experts in the field to ensure scientific integrity and quality. JEP publishes a diverse range of content: Original Research Articles: Groundbreaking studies presenting novel findings in experimental pharmacology. Reviews: Comprehensive assessments of current research trends, methodologies, and
From the journal's Aims & Scope
Research area (LetPub): Medicine-Pharmacology (medical)
Editor-in-chief Abdelwahab OmriPublisher website
Editorial board by country: none in mainland China; most named United States 26, Canada 8, Iraq 6, Italy 2, Türkiye 2 (52 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Medicinal Plant ResearchAgricultural and Biological Sciences27.1%
- Phytochemistry Medicinal Plant ApplicationsAgricultural and Biological Sciences9.8%
- Natural Antidiabetic Agents StudiesMedicine8%
- Ethnobotanical and Medicinal Plants StudiesAgricultural and Biological Sciences5.4%
- Essential Oils and Antimicrobial ActivityAgricultural and Biological Sciences4%
- Phytochemistry and biological activity of medicinal plantsAgricultural and Biological Sciences3.6%
- Wound Healing and TreatmentsMedicine3.4%
- Phytochemistry and Biological ActivitiesAgricultural and Biological Sciences3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology (medical) | Q2 | 99/278 | 64th |
| Pharmacology | Q2 | 139/328 | 57th |
| Molecular Medicine | Q3 | 103/179 | 42nd |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCEmbasePublisher website
Other: The Open Access Initiative (OAIster)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 5.1LetPub ·
- CiteScore (publisher) 2025
- 1.11Publisher website ·
- SJR 2026-06
- 0.57LetPub ·
- SJR (publisher) 2025
- 0.57Publisher website ·
- SNIP 2026-06
- 1.11LetPub ·
- SNIP (publisher) 2025
- 1.11Publisher website ·
- h-index
- 38OpenAlex ·
- i10-index
- 209OpenAlex ·
- 2-year mean citedness
- 3.7OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Downloads per year (publisher)
- 76,574Publisher website ·
Articles by year OpenAlex count · 414 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 22 | 22 | 1,002 |
| 2025 | 51 | 51 | 1,277 |
| 2024 | 36 | 36 | 1,199 |
| 2023 | 43 | 43 | 1,095 |
| 2022 | 32 | 32 | 994 |
| 2021 | 68 | 68 | 687 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
104 daysMedian, submission to acceptance · P25–P75 81 days – 127 days
- Acceptance to online
- median 14 days (75 articles)
- Submission to online
- median 123 days
- Sample
- 75 articles with submission and acceptance dates (77 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 19%Publisher website ·
- Desk decision
- 40 daysPublisher website ·
- Submission to first decision
- 40 daysPublisher website ·
- Acceptance to publication
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,940 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- commentariesCommentaries: Insightful discussions on emerging topics and critical issues in pharmacology.Length not stated
- original research articlesOriginal Research Articles: Groundbreaking studies presenting novel findings in experimental pharmacology.Length not stated
- reportsReports: Concise reports highlighting significant experimental findings.Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewsReviews: Comprehensive assessments of current research trends, methodologies, and advancements in pharmacology.Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Peer review
Single-anonymous peer review Model summary
All submissions undergo rigorous single-anonymous peer review by experts in the field to ensure scientific integrity and quality.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-1454
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Experimental Pharmacology
How long does peer review take at Journal of Experimental Pharmacology?
Based on the dates recorded on 75 articles published between November 2024 and November 2026 (the last 24 months), the median time from submission to acceptance is 104 days (interquartile range 81–127 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 19%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Journal of Experimental Pharmacology based?
Of the 52 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (26), Canada (8) and Iraq (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Experimental Pharmacology?
According to LetPub and DOAJ records, Journal of Experimental Pharmacology is indexed in Scopus and DOAJ. The journal's website also lists PMC and Embase; that list has not been checked against each database.
Is Journal of Experimental Pharmacology open access, and what is the APC?
Journal of Experimental Pharmacology is a fully open-access journal. APC about USD 3,940.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .